この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 1997/5/271 分で読めます
Oral Dosage Form New Animal Drugs; Milbemycin Oxime/Lufenuron Tablets
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Novartis Animal Health US, Inc. The NADA provides for use of milbemycin oxime/lufenuron tablets for prevention of heartworm disease caused by Dirofilaria immitis, control of adult Ancylostoma caninum, the removal and control of adult Toxocara canis, Toxascaris leonina, and Trichuris vulpis infections, and the prevention and control of flea populations in dogs.
情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →